Maze Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(1) Financial Statements
The financial statements required by Item 15(a) are filed as part of this Annual Report on Form 10-K under Item 8 “Financial Statements and Supplementary Data.”
(2) Financial Statement Schedules
The financial statement schedules required by Item 15(a) are omitted because they are not applicable, not required or the required information is included in the financial statements or notes thereto as filed in Item 8 of this Annual Report on Form 10-K.
(3)Exhibits
The following is a list of Exhibits filed, furnished or incorporated by reference as part of the Annual Report on Form 10-K:
| EXHIBIT INDEX | |||||
|---|---|---|---|---|---|
| Incorporated by Reference | |||||
| Exhibitnumber | Description of document | Form | File No. | Number | Filing Date |
| 3.1 · Amended and Restated Certificate of Incorporation. · Filed herewith | |||||
| 3.2 · Amended and Restated Bylaws. · Filed herewith | |||||
| 4.1 | Form of Common Stock Certificate. | S-1/A | 333-284164 | 4.1 | |
| 4.2 | Amended and Restated Investors’ Rights Agreement, dated November 26, 2024, by and among Maze Therapeutics, Inc. and certain of its stockholders. | S-1 | 333-284164 | 4.2 | |
| 10.1 | Form of Indemnity Agreement. | S-1 | 333-284164 | 10.1 | |
| 10.2* | 2018 Stock Option and Grant Plan, as amended, and forms of award agreements. | S-1 | 333-284164 | 10.2 | |
| 10.3* | 2019 Equity Incentive Plan, as amended, and forms of award agreements. | S-1 | 333-284164 | 10.3 | |
| 10.4* | 2025 Equity Incentive Plan, and forms of award agreements. | S-1/A | 333-284164 | 10.4 | |
| 10.5* | 2025 Employee Stock Purchase Plan, and forms of award agreements. | S-1/A | 333-284164 | 10.5 | |
| 10.6^ | Lease Agreement, dated September 27, 2019, by and among Maze Therapeutics, Inc. and HCP Oyster Point III LLC. | S-1 | 333-284164 | 10.6 | |
| 10.7* | Consulting Agreement, dated November 1, 2019, by and among Maze Therapeutics, Inc. and Charles Homcy, M.D. | S-1 | 333-284164 | 10.7 | |
| 10.8* | Advisor Agreement, dated July 1, 2021, by and among Maze Therapeutics, Inc. and Richard Scheller, Ph.D. | S-1 | 333-284164 | 10.8 | |
| 10.9 | Loan and Security Agreement, dated June 27, 2022, by and between Maze Therapeutics, Inc. and Pacific Western Bank, as amended. | S-1 | 333-284164 | 10.9 | |
| 10.10†^ | License Agreement, dated as of March 27, 2024, by and between Maze Therapeutics, Inc. and Shionogi & Co., Ltd. | S-1 | 333-284164 | 10.10 | |
| 10.11 | Non-Employee Director Compensation Policy. | S-1/A | 333-284164 | 10.11 | |
| 10.12* | Restated Offer Letter by and between Maze Therapeutics, Inc. and Jason Coloma, Ph.D., M.P.H. | S-1/A | 333-284164 | 10.12 | |
| 10.13* | Restated Offer Letter by and between Maze Therapeutics, Inc. and Harold Bernstein, M.D., Ph.D. | S-1/A | 333-284164 | 10.13 | |
| 10.14* | Form of Restated Offer Letter between Maze Therapeutics, Inc. and its senior executive officers. | S-1 | 333-284164 | 10.14 | |
| 10.15* | Amended and Restated Executive Severance and Change in Control Plan. | S-1 | 333-284164 | 10.15 | |
| 10.16* | Restated Offer Letter by and between Maze Therapeutics, Inc. and Courtney Phillips. | S-1/A | 333-284164 | 10.16 | |
| 10.17 | Second Amendment to the Loan and Security Agreement, dated March 28, 2025, by and between Maze Therapeutics, Inc. and Banc of California. | Filed herewith | |||
| 19.1 | Insider Trading Policy | Filed herewith | |||
| 21.1 | Subsidiaries of the Registrant | Filed herewith | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm. | Filed herewith | |||
| 24.1 | Power of Attorney (included in signature page). | Filed herewith | |||
| 31.1 | Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith |
| 32.1** | Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Filed herewith |
| 97.1 | Compensation Recovery Policy | Filed herewith |
- Executive compensation plan or agreement.
† The Registrant has omitted portions of the exhibit (indicated by “[***]”) as permitted under Item 601(b)(10) of Regulation S-K.
^ The Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.
** This certification is deemed not filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
(b) Financial statement schedules.
No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.